610 Medizin und Gesundheit
Refine
Year of publication
Document Type
- Article (6062)
- Doctoral Thesis (1980)
- Preprint (281)
- Part of Periodical (244)
- Conference Proceeding (203)
- Book (175)
- Contribution to a Periodical (172)
- Review (58)
- Part of a Book (39)
- Working Paper (17)
Language
- English (6181)
- German (3013)
- Latin (26)
- mis (13)
- Multiple languages (13)
- French (11)
- Portuguese (1)
- Romanian (1)
- Russian (1)
- Spanish (1)
Has Fulltext
- yes (9262) (remove)
Keywords
- inflammation (95)
- COVID-19 (68)
- SARS-CoV-2 (54)
- apoptosis (41)
- cancer (41)
- Inflammation (40)
- glioblastoma (38)
- breast cancer (34)
- autophagy (32)
- Cancer (30)
Institute
- Medizin (7418)
- Pharmazie (297)
- Biowissenschaften (270)
- Präsidium (255)
- Biochemie, Chemie und Pharmazie (233)
- Biochemie und Chemie (216)
- Frankfurt Institute for Advanced Studies (FIAS) (155)
- Georg-Speyer-Haus (130)
- Sportwissenschaften (130)
- Psychologie (94)
Therapierefraktärer Schmerz ist ein weit verbreitetes, äußerst belastendes Leitsymptom rheumatischer Erkrankungen. Viele Betroffene weichen daher bei Versagen der Standardmedikation selbstständig auf Cannabis oder die strukturell verwandte Substanz Palmitoylethanolamid (PEA) als Add-On- oder Alternativtherapie aus, obwohl dies in Deutschland bisher nur eingeschränkt zulässig ist. Die deutsche Gesetzgebung ist diesbezüglich nicht eindeutig, weshalb Ärzt:innen in ihrer Entscheidung, Cannabis zu verschreiben, auf Leitlinien, Fallberichte und Expert:innenmeinungen zurückgreifen müssen. Dies führt zu schwierigen Einzelfallentscheidungen, da sich die derzeitige Datenlage zu Cannabis-based Medicine (CBM) bzw. PEA und Rheuma als mangelhaft darstellt und die Leitlinien dementsprechend keine klaren Empfehlungen enthalten. Ziel der vorliegenden Arbeit ist es, die vorhandene Evidenz zusammenzufassen, zu ordnen und anhand der Hill-Kriterien den möglichen kausalen Zusammenhang zwischen der Einnahme von CBM bzw. PEA und der analgetischen Wirkung bei Rheumaschmerzen zu prüfen.
Background: Novel treatments are needed to control refractory status epilepticus (SE). This study aimed to assess the potential effectiveness of fenfluramine (FFA) as an acute treatment option for SE. We present a summary of clinical cases where oral FFA was used in SE.
Methods: A case of an adult patient with Lennox–Gastaut syndrome (LGS) who was treated with FFA due to refractory SE is presented in detail. To identify studies that evaluated the use of FFA in SE, we performed a systematic literature search.
Results: Four case reports on the acute treatment with FFA of SE in children and adults with Dravet syndrome (DS) and LGS were available. We report in detail a 30-year-old woman with LGS of structural etiology, who presented with generalized tonic and dialeptic seizures manifesting at high frequencies without a return to clinical baseline constituting the diagnosis of SE. Treatment with anti-seizure medications up to lacosamide 600 mg/d, brivaracetam 300 mg/d, valproate 1,600 mg/d, and various benzodiazepines did not resolve the SE. Due to ongoing refractory SE and following an unremarkable echocardiography, treatment was initiated with FFA, with an initial dose of 10 mg/d (0.22 mg/kg body weight [bw]) and fast up-titration to 26 mg/d (0.58 mg/kg bw) within 10 days. Subsequently, the patient experienced a resolution of SE within 4 days, accompanied by a notable improvement in clinical presentation and regaining her mobility, walking with the assistance of physiotherapists. In the three cases reported in the literature, DS patients with SE were treated with FFA, and a cessation of SE was observed within a few days. No treatment-emergent adverse events were observed during FFA treatment in any of the four cases.
Conclusions: Based on the reported cases, FFA might be a promising option for the acute treatment of SE in patients with DS and LGS. Observational data show a decreased SE frequency while on FFA, suggesting a potentially preventive role of FFA in these populations.
Key points
* We summarize four cases of refractory status epilepticus (SE) successfully treated with fenfluramine.
* Refractory SE resolved after 4–7 days on fenfluramine.
* Swift fenfluramine up-titration was well-tolerated during SE treatment.
* Treatment-emergent adverse events on fenfluramine were not observed.
* Fenfluramine might be a valuable acute treatment option for SE in Dravet and Lennox–Gastaut syndromes.
MicroRNAs (miRNAs) are critical post-transcriptional regulators in many biological processes. They act by guiding RNA-induced silencing complexes to miRNA response elements (MREs) in target mRNAs, inducing translational inhibition and/or mRNA degradation. Functional MREs are expected to predominantly occur in the 3’ untranslated region and involve perfect base-pairing of the miRNA seed. Here, we generate a high-resolution map of miR-181a/b-1 (miR-181) MREs to define the targeting rules of miR-181 in developing murine T-cells. By combining a multi-omics approach with computational high-resolution analyses, we uncover novel miR-181 targets and demonstrate that miR-181 acts predominantly through RNA destabilization. Importantly, we discover an alternative seed match and identify a distinct set of targets with repeat elements in the coding sequence which are targeted by miR-181 and mediate translational inhibition. In conclusion, deep profiling of MREs in primary cells is critical to expand physiologically relevant targetomes and establish context-dependent miRNA targeting rules.
Key Points:
* Deep profiling identifies novel targets of miR-181 associated with global gene regulation.
* miR-181 MREs in repeat elements in the coding sequence act through translational inhibition.
* High-resolution analysis reveals an alternative seed match in functional MREs.
The spike protein of SARS-CoV-2 is a highly flexible membrane receptor that triggers the translocation of the virus into cells by attaching to the human receptors. Like other type I membrane receptors, this protein has several extracellular domains connected by flexible hinges. The presence of these hinges results in high flexibility, which consequently results in challenges in defining the conformation of the protein. Here, We developed a new method to define the conformational space based on a few variables inspired by the robotic field’s methods to determine a robotic arm’s forward kinematics. Using newly performed atomistic molecular dynamics (MD) simulations and publicly available data, we found that the Denavit-Hartenberg (DH) parameters can reliably show the changes in the local conformation. Furthermore, the rotational and translational components of the homogenous transformation matrix constructed based on the DH parameters can identify the changes in the global conformation of the spike and also differentiate between the conformation with a similar position of the spike head, which other types of parameters, such as spherical coordinates, fail to distinguish between such conformations. Finally, the new method will be beneficial for looking at the conformational heterogeneity in all other type I membrane receptors.
Understanding the underlying mechanisms that link psychopathology and physical comorbidities in schizophrenia is crucial since decreased physical fitness and overweight pose major risk factors for cardio-vascular diseases and decrease the patients’ life expectancies. We hypothesize that altered reward anticipation plays an important role in this. We implemented the Monetary Incentive Delay task in a MR scanner and a fitness test battery to compare schizophrenia patients (SZ, n = 43) with sex- and age-matched healthy controls (HC, n = 36) as to reward processing and their physical fitness. We found differences in reward anticipation between SZs and HCs, whereby increased activity in HCs positively correlated with overall physical condition and negatively correlated with psychopathology. On the other handy, SZs revealed stronger activity in the posterior cingulate cortex and in cerebellar regions during reward anticipation, which could be linked to decreased overall physical fitness. These findings demonstrate that a dysregulated reward system is not only responsible for the symptomatology of schizophrenia, but might also be involved in physical comorbidities which could pave the way for future lifestyle therapy interventions.
Spezialwissen für SCALE
(2024)
Volker Zickermann und Eric Helfrich sind bei der Exzellenzcluster-Initiative SCALE (Subcellular Architecture of Life) dabei und werden dort ihre Expertise einbringen. Das Spezialgebiet des einen ist ein Proteinkomplex in den Mitochondrien, den Kraftwerken der Zelle. Der andere sucht schwerpunktmäßig bisher unbekannte Naturstoffe, die die Basis für neue Antibiotika sein könnten.
Herzforschung meets KI
(2024)
Moderne Methoden der Künstlichen Intelligenz (KI) spielen in der Wissenschaft eine immer größere Rolle. Wie Forscher des Exzellenzclusters Cardio-Pulmonary Institute (CPI) KI in der Herzbildgebung nutzen, zeigte Professor Eike Nagel im Rahmen der Bürgeruniversität der Goethe-Universität. Er leitet das Institut für experimentelle und translationale kardiovaskuläre Bildgebung am Fachbereich Medizin und forscht an der Entwicklung verbesserter Behandlungsmöglichkeiten für Herz-Kreislauf-Erkrankungen. Mit dem Ziel, seine Forschung für alle Menschen zugänglich und verständlicher zu machen, lud Prof. Nagel interessierte Bürger*innen am 10. Mai in sein Institut ein.
Der unter der Ägide der Freunde und Förderer der Goethe-Universität von der Paul Ehrlich-Stiftung ausgelobte Paul Ehrlich-und-Ludwig Darmstaedter-Preis ist die renommierteste Auszeichnung, die in Deutschland für medizinische Forschung verliehen wird. Den mit 120.000 Euro dotierten Preis nahm in der Frankfurter Paulskirche in diesem Jahr der Arzt und Immunologe Prof. Dennis L. Kasper (81) von der Harvard Medical School entgegen. Er hat die ersten Wörter der biochemischen Sprache entdeckt, mit der Darmbakterien unserem Immunsystem zu einer gesunden Entwicklung verhelfen. Den mit 60.000 Euro dotierten Nachwuchspreis erhielt der Chemiker Dr. Johannes Karges (31) von der Ruhr-Universität Bochum für die Entwicklung eines Verfahrens zur ferngesteuerten Tumortherapie.